Cytokine production-inducing antibody
CA 2498315 C · Owner: Glacet, Arnaud · Inventors: De Romeuf, Christophe; Bourel, Dominique; Glacet, Arnaud
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a method of measuring the activation of an effector cell belonging to the immune system which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins such as IFN? or IL2 which are intended for the treatment of autoimmune …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 15, 2003 and granted January 29, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 15, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 15, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.